Drug intelligence / Profile preview

Academy of Military Medical Sciences TRPM2 compound 8

Development stage: Unknown
Lead developer: Academy of Military Medical Sciences

Overview

Academy of Military Medical Sciences TRPM2 compound 8: sourced facts only. name: "Collectively, selective TRPM2 inhibitors, especially compound 8, are promising candidates, providing experimental evidence for TRPM2-targeted ALI therapy." [PMID:42700809]; target: "Collectively, selective TRPM2 inhibitors, especially compound 8, are promising candidates, providing experimental evidence for TRPM2-targeted ALI therapy." [PMID:42700809]; developer: "State Key Laboratory of National Security Specially Needed Medicines, NO 100 Yongding Road, Beijing, 100039, China; Academy of Military Medical Sciences, NO 27 Taiping Road, Beijing, 100850, China." [PMID:42700809]

Targets

TRPM2 (Transient receptor potential cation channel subfamily M member 2)

Beyond the preview

Go deeper on Academy of Military Medical Sciences TRPM2 compound 8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Academy of Military Medical Sciences TRPM2 compound 8.